Valuation: Sagimet Biosciences Inc.

Market Cap 689M 602M 566M 517M 970M 65.9B 970M 6.8B 2.62B 33.65B 2.59B 2.53B 108B P/E 2026 *
-9.48x
P/E 2027 * -7.98x
Enterprise Value 461M 403M 379M 345M 648M 44.06B 648M 4.54B 1.75B 22.5B 1.73B 1.69B 72.53B EV / Sales 2026 *
-
EV / Sales 2027 * 72.4x
Free-Float
95.77%
Yield 2026 *
-
Yield 2027 * -
1 week+6.02%
Current month+8.09%
1 month+8.20%
3 months+56.20%
6 months+130.08%
Current year+87.33%
1 week 10.25
Extreme 10.25
11.4
1 month 9.95
Extreme 9.95
11.45
3 years 1.73
Extreme 1.73
20.71
Manager TitleAgeSince
Chief Executive Officer 64 2022-10-23
Director of Finance/CFO 50 2024-05-05
Chief Tech/Sci/R&D Officer 65 2026-04-19
Director TitleAgeSince
Director/Board Member 69 2007-03-31
Chairman 65 2022-10-23
Director/Board Member 62 2021-04-30
Change 5-day change 1-year change 3-year change Capi.($)
+2.69%+6.02%+62.85%+13.98% 689M
-0.07%+7.14%+53.95%+111.00% 74.27B
-0.33%+0.47%+35.98%+78.67% 61.21B
+0.28%+5.73%+33.67%+20.82% 27.55B
-0.15%+0.75%-16.69%+361.67% 26.38B
+2.93%+4.32%+2.18%-3.60% 25.34B
+1.27%+4.34%+26.41%-8.49% 20.84B
-1.47%+4.86%-5.94%+519.63% 14.94B
+0.87%-3.73%+159.95%+327.53% 15.17B
+1.63%+2.20%+46.92%+170.72% 14.41B
Average +0.56%+3.17%+39.93%+159.19% 31.12B
Weighted average by Cap. +0.34%+3.44%+36.89%+135.72%

Financials

2026 *2027 *
Net sales - 7.56M 6.6M 6.21M 5.66M 10.63M 722M 10.63M 74.49M 28.74M 369M 28.38M 27.76M 1.19B
Net income -58.6M -51.21M -48.13M -43.92M -82.43M -5.6B -82.44M -578M -223M -2.86B -220M -215M -9.22B -85.17M -74.43M -69.95M -63.83M -120M -8.14B -120M -840M -324M -4.16B -320M -313M -13.4B
Net Debt -228M -200M -188M -171M -321M -21.84B -321M -2.25B -869M -11.16B -858M -839M -35.96B -143M -125M -117M -107M -201M -13.63B -201M -1.41B -542M -6.96B -536M -524M -22.44B
Logo Sagimet Biosciences Inc.
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.
Employees
-
Date Price Change
26-09-22 US$11.09 +2.69%
26-09-21 US$10.80 -2.61%
26-09-18 US$11.09 -0.72%
26-09-17 US$11.17 +6.79%
26-09-16 US$10.46 0.00%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
11.09USD
Average target price
29.60USD
Spread / Average Target
+166.91%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!